Abstract: Methods and applications of the present disclosure include promoting blood clotting, controlling hemorrhage, and or inhibiting fibrinolysis in soldiers and civilians having experienced massive bleeding from a wound by administering antifibrinolytic agents, such as tranexamic acid, and or one or more procoagulants, in preferably autoinjector format.

Abstract: A first source of medical gas has a generally cylindrical male outlet with a cylindrical bore and a threaded outer cylindrical surface. A flexible cylindrical elastomeric medical gas tubing has an input end with a bushing making a flush abutment with the male outlet at the output orifice. An output end attaches to any of a plurality of medical gas utilizing devices, but preferably with a dampening disperser held in position in the space in the vicinity of a patient's nose and mouth. An annular flange of the input end bushing resides within a central cylindrical bored out region extending through the first end and nearly to the second end of a rotatable connector forming an interior surface of a connector with threads coupling with the threads of the male outlet. The second end is an annular abutment against the annular flange holding the input end tubing bushing against the outlet source and providing an airtight coupling. A gripping means is on the exterior surface of the connector.

Abstract: The present disclosure describes a flavor element configured for providing flavor to a user of an electronic vaporizer, along with nicotine reduction methods. The flavor element includes a flavor material configured to provide the flavor and is configured to attach to the electronic vaporizer. When attached to the electronic vaporizer and during inhalation by the user using the electronic vaporizer, the flavor element is configured to provide the flavor to the user in parallel with an inhalable aerosol provided by the electronic vaporizer. The inhalable aerosol is provided by the electronic vaporizer by at least partially vaporizing a vaporizable substance via a vapor element. The flavor provided via the flavor material is separate from the vaporizable substance.

Abstract: The present disclosure describes a flavor element configured for providing flavor to a user of an electronic vaporizer, along with nicotine reduction methods. The flavor element includes a flavor material configured to provide the flavor and is configured to attach to the electronic vaporizer. When attached to the electronic vaporizer and during inhalation by the user using the electronic vaporizer, the flavor element is configured to provide the flavor to the user in parallel with an inhalable aerosol provided by the electronic vaporizer. The inhalable aerosol is provided by the electronic vaporizer by at least partially vaporizing a vaporizable substance via a vapor element. The flavor provided via the flavor material is separate from the vaporizable substance.

Abstract: A first source of medical gas has a generally cylindrical male outlet with a cylindrical bore and a threaded outer cylindrical surface. A flexible cylindrical elastomeric medical gas tubing has an input end with a bushing making a flush abutment with the male outlet at the output orifice. An output end attaches to any of a plurality of medical gas utilizing devices, but preferably with a dampening disperser held in position in the space in the vicinity of a patient's nose and mouth. An annular flange of the input end bushing resides within a central cylindrical bored out region extending through the first end and nearly to the second end of a rotatable connector forming an interior surface of a connector with threads coupling with the threads of the male outlet. The second end is an annular abutment against the annular flange holding the input end tubing bushing against the outlet source and providing an airtight coupling. A gripping means is on the exterior surface of the connector.

Abstract: The present invention provides methods of non-gastrointestinal transmucosal drug delivery that secures, sheaths, and protects vasoconstricting and or adrenergic drug from mixing with saliva and being swallowed, thereby preventing both decreased bioavailability and loss of efficacy, and ensuring restoration of proper blood perfusion. In preferred embodiments, the adrenergic drug is epinephrine and the method treats hypotension associated with anaphylaxis.

Abstract: The present invention provides pharmaceutical formulations of levorotatory-epinephrine, l-epinephrine, more potent and less toxic than existing pharmaceutical formulations of epinephrine, along with methods of producing and using these pharmaceutical formulations of l-epinephrine, including preventing and or treating hypotension and hemostasis under surgical anesthesia.

Abstract: An example aerosol delivery device includes a mouthpiece having an airflow outlet, and an airflow passage extending between an airflow inlet and the airflow outlet. The example aerosol delivery device further includes a housing configured to receive a cartridge that includes an aerosolizable substance and a vapor element configured to heat the aerosolizable substance, and an internal power source configured to provide electrical power. The example aerosol delivery device further includes a controller coupled to the internal power source to receive a portion of the electrical power and configured to, when the cartridge is installed at the housing, cause the vapor element of the cartridge to heat the aerosolizable substance to release an aerosol into the airflow passage during an inhalation through the airflow outlet, and a connector configured to receive power from an external source to recharge the internal power source.

Abstract: The present invention provides pharmaceutical formulations of levorotatory-epinephrine, 1-epinephrine, more potent and less toxic than existing pharmaceutical formulations of epinephrine, along with methods of producing and using these pharmaceutical formulations of 1-epinephrine, including preventing and or treating hypotension and hemostasis under surgical anesthesia.

Abstract: An example aerosol delivery device includes a mouthpiece having an airflow outlet, and an airflow passage extending between an airflow inlet and the airflow outlet. The example aerosol delivery device further includes a housing configured to receive a cartridge that includes an aerosolizable substance and a vapor element configured to heat the aerosolizable substance, and an internal power source configured to provide electrical power. The example aerosol delivery device further includes a controller coupled to the internal power source to receive a portion of the electrical power and configured to, when the cartridge is installed at the housing, cause the vapor element of the cartridge to heat the aerosolizable substance to release an aerosol into the airflow passage during an inhalation through the airflow outlet, and a connector configured to receive power from an external source to recharge the internal power source.

Abstract: A liquid injectable pharmaceutical drug product consisting of no less that 99 percent ethanol comprised of no less than 99 percent ethanol active pharmaceutical ingredient with a volume of at least 0.05 mL to be injected into a patient as a method of ablating/lysing cells.

Abstract: Methods of the present disclosure utilize alcohol (e.g., ethanol) as an active ingredient or agent for disinfecting, washing, and/or treating infection in the upper and/or lower airways. Methods include aerosol inhalation, lung spraying, and/or lung lavage using ethanol-containing solutions. Such methods can be applied to complicated pneumonia and respiratory pandemics, including the COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Abstract: The present invention relates to longitudinally sectioned bullets and methods that pertain to a penetrable projectile structured to be discharged from a firearm and comprising at least two separable and penetrable, non-fused individual longitudinal body sections and at least one exterior binding element, including at the frontal region of said penetrable projectile, that holds the at least two non-fused individual longitudinal body sections together until they rupture inside of a target, thereby causing the penetrable individual longitudinal body sections to separate away from each other inside of the target as the projectile penetrates the target. The penetrable projectile is thus capable of controlled fragmentation against a soft target, and is optionally adapted to deliver at least one supplemental payload to a target to further damage said target.

Abstract: A liquid injectable pharmaceutical drug product consisting of no less than 99 percent ethanol comprised of no less than 99 percent ethanol active pharmaceutical ingredient with a volume of at least 0.05 mL to be injected into a patient as a method of ablating/lysing cells.

Abstract: A bullet projectile, not limited to a hollow point bullet, is made into a biological active bullet before loading and firing from a firearm with a method of incorporating an at least one biological active payload into an at least one externally facing cavity or channel of the bullet projectile to enhance the damage and lethality of the bullet projectile to produce at least one of embolism, infarct, necrosis, hemorrhage, enhanced loss of perfusion, anticoagulation, or a combination thereof in a target.

Abstract: The present disclosure describes a flavor element configured for providing flavor to a user of an electronic vaporizer, along with nicotine reduction methods. The flavor element includes a flavor material configured to provide the flavor and is configured to attach to the electronic vaporizer. When attached to the electronic vaporizer and during inhalation by the user using the electronic vaporizer, the flavor element is configured to provide the flavor to the user in parallel with an inhalable aerosol provided by the electronic vaporizer. The inhalable aerosol is provided by the electronic vaporizer by at least partially vaporizing a vaporizable substance via a vapor element. The flavor provided via the flavor material is separate from the vaporizable substance.

Abstract: The present disclosure provides methods of mimicking epinephrine plasma pharmacokinetic parameters/plasma epinephrine levels of an at least one l-epinephrine injection in humans with an at least one dosage of an intranasal and/or sublingual l-epinephrine formulation. Methods of maintaining constant elevated plasma epinephrine level(s) by the consecutive dosing of intranasal and/or sublingual l-epinephrine are also provided. These methods may be helpful when l-epinephrine injection is not available or not possible. The present disclosure allows formulations for intranasal administration of l-epinephrine and/or small, l-epinephrine sublingual tablets to be conveniently carried by soldiers and others, such as in a remote location or battlefield, and such as when emergency medical services are not readily available or accessible. The methods may be able to sustain life and restore proper blood perfusion when someone is having cardiopulmonary difficulty until medical help or transport can arrive.

Abstract: The present disclosure provides methods of mimicking epinephrine plasma pharmacokinetic parameters/plasma epinephrine levels of an at least one l-epinephrine injection in humans with an at least one intranasal dosage of an inhalable l-epinephrine formulation adapted for transmucosal absorption. Dosages for sublingual or buccal absorption and/or oral inhalation are also provided. These methods may be helpful when l-epinephrine injection is not available or not possible. The present disclosure also provides methods of pretreating breathing difficulty before intranasal treatment of anaphylaxis. The present disclosure allows formulations for intranasal administration of l-epinephrine to be conveniently carried by soldiers and others, such as in a remote location or battlefield, and such as when emergency medical services are not readily available or accessible.

Abstract: An example aerosol delivery device includes a mouthpiece having an airflow outlet, and an airflow passage extending between an airflow inlet and the airflow outlet. The example aerosol delivery device further includes a housing configured to receive a cartridge that includes an aerosolizable substance and a vapor element configured to heat the aerosolizable substance, and an internal power source configured to provide electrical power. The example aerosol delivery device further includes a controller coupled to the internal power source to receive a portion of the electrical power and configured to, when the cartridge is installed at the housing, cause the vapor element of the cartridge to heat the aerosolizable substance to release an aerosol into the airflow passage during an inhalation through the airflow outlet, and a connector configured to receive power from an external source to recharge the internal power source.

Abstract: The present invention provides novel methods of mimicking epinephrine plasma pharmacokinetic parameters/plasma epinephrine levels of an at least one l-epinephrine injection in humans with an at least one dosage of a sublingual l-epinephrine formulation; and includes methods of maintaining constant elevated plasma epinephrine level(s) by the consecutive dosing of sublingual l-epinephrine. These methods are especially important when l-epinephrine injection is not available or not possible. The present invention allows small, l-epinephrine sublingual tablets to be carried by soldiers and others, such as in a remote location or battlefield, when emergency medical services are not readily available or accessible. The inventive methods can sustain life and restore proper blood perfusion when someone is having cardiopulmonary difficulty until medical help or transport can arrive.